Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Xiaomi Shares Jump on Europe EV Expansion Plan 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to report full-year 2017 financial results and provide an operational update on March 7, 2018, after the NASDAQ market close.
Conference Call/Webcast Information
Interested parties may access the live audio webcast of the teleconference at 5:00 p.m. ET through the Investor and News page of CytomX's website at http://ir.cytomx.com or by dialing 1-877-809-6037 and using the passcode 5686339. A replay will be available on the CytomX website or by dialing
1-855-859-2056 and using the passcode 5686339. The replay will be available from March 7, 2018, until March 14, 2018.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as PD-L1 and CTLA-4, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Media:
Spectrum
Christine Quern
[email protected]
202-587-2588
Investors:
Trout Group
Pete Rahmer
[email protected]
646-378-2973
